ORTX Orchard Therapeutics plc

+0.17  (+1%)
Previous Close 15.61
Open 16
Price To Book 87.66
Market Cap 1326138745
Shares 84,047,200
Volume 140,251
Short Ratio
Av. Daily Volume 53,280

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data to be presented February 24, 2019 12 noon CT.
X-linked chronic granulomatous disease (X-CGD)
Phase 1/2 data to be presented February 22, 2019 9:30a.m. CT.
Adenosine deaminase severe combined immunodeficiency (ADA-SCID)

Latest News

  1. Orchard Therapeutics Presents Two-Year Follow-Up Data Versus Historical Control from Registrational Trial of OTL-101 for the Treatment of ADA-SCID
  2. Orchard Therapeutics Announces Acceptance of Late-Breaking Abstracts of OTL-101 for ADA-SCID and OTL-102 for X-CGD at the 2019 Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR
  3. Orchard Announces Publication by San Raffaele-Telethon Institute for Gene Therapy of OTL-300 Clinical Data for the Treatment of Transfusion-Dependent Beta-Thalassemia in Nature Medicine
  4. Orchard Therapeutics Highlights Recent Accomplishments and 2019 Strategic Priorities as a Global Leader in Gene Therapy
  5. Orchard Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019
  6. 2019 biotech preview: Money is pouring into the Bay Area and so is Big Pharma
  7. Positive Data From Orchard Therapeutics Turns Goldman Sachs Bullish
  8. Targeting 'bubble baby' disease, this gene therapy company is planting a flag in the East Bay
  9. Orchard Therapeutics Announces the Build-out of New Gene Therapy Manufacturing Facility in California
  10. Orchard Therapeutics Appoints Industry Veteran Alicia Secor to its Board of Directors
  11. Donald B. Kohn, MD, Orchard Therapeutics Scientific Advisory Board Member, Presents Clinical Proof-of-Concept Data for OTL-102 Gene Therapy for the Treatment of Patients with X-CGD at the Presidential Symposium at the 2018 ASH Annual Meeting
  12. Orchard Therapeutics Announces Pricing of Initial Public Offering
  13. IPO Outlook For The Week: Banks And Biotechs